Welireg (belzutifan tablets - Merck) — Cigna

Initial criteria

• Patient is age ≥ 18 years; AND
• Patient has a von Hippel-Lindau (VHL) germline alteration as detected by genetic testing; AND
• Patient does not require immediate surgery; AND
• Patient requires therapy for ONE of the following conditions (central nervous system hemangioblastomas OR pancreatic neuroendocrine tumors OR renal cell carcinoma OR retinal hemangioblastoma)

Approval duration

1 year